Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2023

01-12-2023 | Secukinumab | Case report

Secukinumab

Inflammatory bowel disease

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Guiying W, et al. Inflammatory bowel disease induced by secukinumab. [Chinese] Adverse drug reactions journal 25: 574-576, Sep 2023. Available from: URL: https://dx.doi.org/10.3760/cma.j.cn114015-20221008-00922 [Chinese; summarised from English abstract]
Metadata
Title
Secukinumab
Inflammatory bowel disease
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-52130-7

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

News item

Other adverse reaction research

Case report

Cotrimoxazole/methylprednisolone

Case report

Carfilzomib/prednisolone

Case report

Tozinameran

Case report

Ciprofloxacin/prednisone

Case report

Multiple drugs